Neuren Pharmaceuticals Limited (OTCMKTS:NURPF) Stock Short Interest Jumps 185.6%

Neuren Pharmaceuticals Limited (OTCMKTS:NURPF) was the target of a large increase in short interest during the month of October. As of October 30th, there was short interest totaling 288,479 shares, an increase of 185.6% from the October 15th total of 101,010 shares. Based on an average trading volume of 1 shares, the short-interest ratio is currently 288,479.0 days.

Neuren Pharmaceuticals Price Performance

NURPF stock opened at C$13.76 on Friday. The business has a fifty day moving average price of C$14.56 and a 200 day moving average price of C$11.65. Neuren Pharmaceuticals has a fifty-two week low of C$7.70 and a fifty-two week high of C$17.25.

Neuren Pharmaceuticals Company Profile

Neuren Pharmaceuticals is an Australian biopharmaceutical company focused on developing treatments for serious neurodevelopmental disorders. Based in Melbourne, the company’s research centers on therapies intended to address conditions with limited treatment options. Its lead partnered medicine, trofinetide, is marketed in the United States by Acadia Pharmaceuticals as DAYBUE for Rett syndrome. Neuren developed the drug and licensed commercialization rights to Acadia. Neuren is also developing NNZ-2591, an investigational treatment being studied for several neurodevelopmental conditions, including Phelan-McDermid syndrome, Pitt-Hopkins syndrome, Angelman syndrome and Prader-Willi syndrome.